Norfolk entrepreneur Tait Pollack from Norwich has credited sleep for saving his life after recovering from a life-threatening illness following ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

AstraZeneca's lengthy and turbulent development ... The CTLA4 inhibitor – now given the brand name Imjudo – is only the second drug in the class to be approved after Bristol-Myers Squibb's ...

I pine for the good old days of man flu, where the slightest symptom, a cough, a sniffle or a general sense of malaise, could ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

AstraZeneca has added to its oncology pipeline ... and Mirati’s Krazati (adagrasib), which have been approved as second-line therapies for KRAS-mutated non-small cell lung cancer (NSCLC ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

The second scenario consisted of cases in which people received a booster dose of CoronaVac as well ... there are also the viral vector vaccines (AstraZeneca and Janssen), in which another ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...